Winton Group’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $231K | Sell |
4,207
-12,734
| -75% | -$700K | 0.01% | 729 |
|
|
2025
Q1 | $1.2M | Buy |
16,941
+267
| +2% | +$18.9K | 0.07% | 273 |
|
|
2024
Q4 | $1.1M | Sell |
16,674
-4,639
| -22% | -$305K | 0.07% | 282 |
|
|
2024
Q3 | $1.5M | Buy |
21,313
+15,125
| +244% | +$1.06M | 0.11% | 164 |
|
|
2024
Q2 | $509K | Buy |
+6,188
| New | +$509K | 0.03% | 423 |
|
|
2023
Q4 | – | Sell |
-20,712
| Closed | -$1.83M | – | 746 |
|
|
2023
Q3 | $1.83M | Buy |
20,712
+16,494
| +391% | +$1.46M | 0.15% | 110 |
|
|
2023
Q2 | $366K | Sell |
4,218
-16,749
| -80% | -$1.45M | 0.03% | 454 |
|
|
2023
Q1 | $2.04M | Buy |
20,967
+1,612
| +8% | +$157K | 0.12% | 213 |
|
|
2022
Q4 | $2M | Sell |
19,355
-7,494
| -28% | -$776K | 0.13% | 202 |
|
|
2022
Q3 | $2.28M | Sell |
26,849
-8,504
| -24% | -$721K | 0.15% | 170 |
|
|
2022
Q2 | $2.93M | Buy |
35,353
+23,649
| +202% | +$1.96M | 0.16% | 174 |
|
|
2022
Q1 | $902K | Buy |
11,704
+2,164
| +23% | +$167K | 0.05% | 505 |
|
|
2021
Q4 | $843K | Sell |
9,540
-8,515
| -47% | -$752K | 0.05% | 518 |
|
|
2021
Q3 | $1.4M | Buy |
18,055
+6,098
| +51% | +$471K | 0.08% | 342 |
|
|
2021
Q2 | $998K | Buy |
11,957
+637
| +6% | +$53.2K | 0.05% | 526 |
|
|
2021
Q1 | $855K | Buy |
11,320
+3,120
| +38% | +$236K | 0.05% | 557 |
|
|
2020
Q4 | $719K | Sell |
8,200
-24,574
| -75% | -$2.15M | 0.05% | 595 |
|
|
2020
Q3 | $2.49M | Sell |
32,774
-22,949
| -41% | -$1.75M | 0.08% | 425 |
|
|
2020
Q2 | $6.87M | Buy |
55,723
+25,453
| +84% | +$3.14M | 0.18% | 113 |
|
|
2020
Q1 | $2.56M | Buy |
+30,270
| New | +$2.56M | 0.07% | 487 |
|
|
2017
Q4 | – | Sell |
-89,673
| Closed | -$8.35M | – | 665 |
|
|
2017
Q3 | $8.35M | Buy |
89,673
+87,223
| +3,560% | +$8.12M | 0.27% | 96 |
|
|
2017
Q2 | $223K | Buy |
+2,450
| New | +$223K | 0.01% | 587 |
|